A study has reported that loss-of-function mutations in the PBRM1 gene were associated with the clinical benefit of using PD-1 inhibitor because PBAF loss shows that RCC is more sensitive to T-cell-mediated cytotoxicity than its PBAF-intact counterparts. The gene discussed is PBRM1; the disease is renal cell carcinoma.